BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 11840294)

  • 1. Point mutations of the BCL-6 gene: clinical and prognostic correlation in B-diffuse large cell lymphoma.
    Vitolo U; Botto B; Capello D; Vivenza D; Zagonel V; Gloghini A; Novero D; Parvis G; Calvi R; Ariatti C; Milan I; Bertini M; Boccomini C; Freilone R; Pregno P; Orsucci L; Palestro G; Saglio G; Carbone A; Gallo E; Gaidano G
    Leukemia; 2002 Feb; 16(2):268-75. PubMed ID: 11840294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of primary mediastinal large B-cell lymphomas].
    Schneider T; Tóth E; Molnár Z; Várady E; Deák B; Horváth A; Horváth GI; Eid H; Schneider K; Lovey J; Keresztes S; Esik O; Lengyel Z; Rosta A
    Orv Hetil; 2004 Dec; 145(50):2531-7. PubMed ID: 15662753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.
    Jerkeman M; Anderson H; Dictor M; Kvaløy S; Akerman M; Cavallin-Ståhl E;
    Ann Hematol; 2004 Jul; 83(7):414-9. PubMed ID: 15085385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group.
    Arranz R; Conde E; Grande C; Mateos MV; Gandarillas M; Albo C; Lahuerta JJ; Fernández-Rañada JM; Hernández MT; Alonso N; García Vela JA; Garzón S; Rodríguez J; Caballero D;
    Eur J Haematol; 2008 Mar; 80(3):227-35. PubMed ID: 18088400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenetic and clinical implications of Bcl-6 and Bcl-2 gene configuration in nodal diffuse large B-cell lymphomas.
    Pescarmona E; De Sanctis V; Pistilli A; Pacchiarotti A; Martelli M; Guglielmi C; Mandelli F; Baroni CD; Le Coco F
    J Pathol; 1997 Nov; 183(3):281-6. PubMed ID: 9422982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B.
    Todeschini G; Secchi S; Morra E; Vitolo U; Orlandi E; Pasini F; Gallo E; Ambrosetti A; Tecchio C; Tarella C; Gabbas A; Gallamini A; Gargantini L; Pizzuti M; Fioritoni G; Gottin L; Rossi G; Lazzarino M; Menestrina F; Paulli M; Palestro M; Cabras MG; Di Vito F; Pizzolo G
    Br J Cancer; 2004 Jan; 90(2):372-6. PubMed ID: 14735179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BCL-6 in diffuse large-cell lymphomas.
    Dalla-Favera R; Ye BH; Cattoretti G; Lo Coco F; Chang CC; Zhang J; Migliazza A; Cechova K; Niu H; Chaganti S; Chen W; Louie DC; Offit K; Chaganti RS
    Important Adv Oncol; 1996; ():139-48. PubMed ID: 8791133
    [No Abstract]   [Full Text] [Related]  

  • 8. High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an "Intergruppo Italiano Linfomi" randomized trial.
    Vitolo U; Liberati AM; Cabras MG; Federico M; Angelucci E; Baldini L; Boccomini C; Brugiatelli M; Calvi R; Ciccone G; Genua A; Deliliers GL; Levis A; Parvis G; Pavone E; Salvi F; Sborgia M; Gallo E;
    Haematologica; 2005 Jun; 90(6):793-801. PubMed ID: 15951292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of an early intensification treatment integrating chemotherapy, autologous stem cell transplantation and radiotherapy for poor risk primary mediastinal large B cell lymphoma with sclerosis.
    Cairoli R; Grillo G; Tedeschi A; Gargantini L; Marenco P; Tresoldi E; Barbarano L; Nosari AM; Morra E
    Bone Marrow Transplant; 2002 Mar; 29(6):473-7. PubMed ID: 11960265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
    Mohammad RM; Wall NR; Dutcher JA; Al-Katib AM
    Clin Cancer Res; 2000 Dec; 6(12):4950-6. PubMed ID: 11156256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
    Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
    Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.
    Natkunam Y; Farinha P; Hsi ED; Hans CP; Tibshirani R; Sehn LH; Connors JM; Gratzinger D; Rosado M; Zhao S; Pohlman B; Wongchaowart N; Bast M; Avigdor A; Schiby G; Nagler A; Byrne GE; Levy R; Gascoyne RD; Lossos IS
    J Clin Oncol; 2008 Jan; 26(3):447-54. PubMed ID: 18086797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. pY-STAT3 and p53 expression predict outcome for poor prognosis diffuse large B-cell lymphoma treated with high dose chemotherapy and autologous stem cell transplantation.
    Stewart DA; Bahlis N; Mansoor A
    Leuk Lymphoma; 2009 Aug; 50(8):1276-82. PubMed ID: 19562614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations of the 5' noncoding region of the BCL-6 gene in primary bone lymphomas.
    Gianelli U; Ponzoni M; Moro A; Alfano RM; Pellegrini C; Giardini R; Patriarca C; Armiraglio E; Bosari S; Parafioriti A; Coggi G
    Ann Hematol; 2003 Nov; 82(11):691-5. PubMed ID: 14513282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Membrane PKC-beta 2 protein expression predicts for poor response to chemotherapy and survival in patients with diffuse large B-cell lymphoma.
    Espinosa I; Briones J; Bordes R; Brunet S; Martino R; Sureda A; Prat J; Sierra J
    Ann Hematol; 2006 Sep; 85(9):597-603. PubMed ID: 16830142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
    van Imhoff GW; van der Holt B; Mackenzie MA; Van't Veer MB; Wijermans PW; Ossenkoppele GJ; Schouten HC; Sonneveld P; Steijaert MM; Kluin PM; Kluin-Nelemans HC; Verdonck LF;
    J Clin Oncol; 2005 Jun; 23(16):3793-801. PubMed ID: 15809447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma.
    Sohn SK; Jung JT; Kim DH; Kim JG; Kwak EK; Park Ti; Shin DG; Sohn KR; Lee KB
    Am J Hematol; 2003 Jun; 73(2):101-7. PubMed ID: 12749011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma.
    Kramer MH; Hermans J; Wijburg E; Philippo K; Geelen E; van Krieken JH; de Jong D; Maartense E; Schuuring E; Kluin PM
    Blood; 1998 Nov; 92(9):3152-62. PubMed ID: 9787151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction between BCL2 and interleukin-10 gene polymorphisms alter outcomes of diffuse large B-cell lymphoma following rituximab plus CHOP chemotherapy.
    Park YH; Sohn SK; Kim JG; Lee MH; Song HS; Kim MK; Jung JS; Lee JJ; Kim HJ; Kim DH
    Clin Cancer Res; 2009 Mar; 15(6):2107-15. PubMed ID: 19276283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients.
    Culpin RE; Sieniawski M; Angus B; Menon GK; Proctor SJ; Milne P; McCabe K; Mainou-Fowler T
    Histopathology; 2013 Dec; 63(6):788-801. PubMed ID: 24117687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.